[Podcast] Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?

May 31, 2024 | North Carolina, USA | Listen to Podcast

Perceiv AI Raises the Bar with ISO 27001 Certification

May 7, 2024 | Montreal, Canada | Press release

Presentation of AD-Px™ to accelerate trials by reducing screen failure rate at the AD/PD conference

March 9, 2024 | Lisbon, Portugal | See presentation

Perceiv AI Partners with Alleo Labs to Optimize Clinical Trials Using Advanced AI and Prognostic Biomarkers

January 8, 2024 | San Francisco, USA | Press release

Perceiv AI Achieves HIPAA Compliance, Reinforcing Commitment to Data Security and Privacy

November 28, 2023 | Montreal, Canada | Press release

Perceiv's CEO, Christian Dansereau, Ph.D., delves deep into "The Future of AI-Powered Clinical Insights", as part of StartUp Health's panel discussion

November 13, 2023 | Las Vegas, USA | StartUp Health

New results presented at CTAD 2023 "Reducing screen failure rates due to biomarker cut-offs in early Alzheimer's disease trials using a prognostic model"

October 24, 2023 | Clinical Trials on Alzheimer's Disease conference (CTAD) | Poster

JLABS J&J innovation 

Perceiv AI Joins Johnson & Johnson Innovation–JLABS Global Network to Accelerate Precision Medicine Platform Development

June 21, 2023 | Toronto, Canada | Annoucement

Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort

January 17, 2023 | Boston, USA | Announcement

Perceiv AI announces an investment of $1.5M from strategic and institutional investors to support the expansion of its prognostic platform Foresight.

December 8, 2022 | Montréal, Canada | Press release

Perceiv AI today announced the closing of an investment of $1.5M. Perceiv AI is a precision medicine company optimizing and de-risking clinical trials and enabling physicians to make a timely diagnosis of degenerative brain disorders by forecasting disease evolution.

The round was composed of strategic and institutional investors from Canada and the US, including CABHI (Centre for Aging + Brain Health Innovation), Plug and Play Ventures, Boreal Ventures, IKJ Capital, Red Abbey Labs, Investissement Québec, as a representative of the government of Quebec, as well as angel investors. "We are very excited to move forward to the next phase of our growth with the support of these strategically important investors," said Dr. Christian Dansereau, CEO of Perceiv AI.

The funds will be used to expand the Foresight platform, Perceiv AI's proprietary AI/ML-driven prognostic platform that predicts disease progression. The company aims to add other key resources by bringing additional talent to the team to advance its commercial and scientific activities and strengthen its regulatory effort.

Perceiv AI Leverages Big Data and Artificial Intelligence to Predict Disease Progression and Make Clinical Trials More Effective

December 2, 2022 | Montréal, Canada | Press release

Perceiv AI to present its latest results on mitigating loss of statistical power due to outcome imbalance in clinical trials

November 24, 2022 | Montréal, Canada | Announcement

Join Perceiv AI's senior scientist Angela Tam at our poster #LP005 "Mitigating loss of statistical power due to outcome imbalance in clinical trials" on Tuesday November 29 to Wednesday November 30 at Clinical Trials on Alzheimer's Disease (CTAD) 2022. Our team is excited to meet you in San Francisco, California next week.

Oral presentation at Alzheimer's Association International Conference (AAIC 2022)

July 18, 2022 | Montréal, Canada

Join Senior Scientist Dr. Angela Tam as she will give a talk on Perceiv AI’s latest work and performance gain for trial optimization and patients selection at the 2022 Alzheimer's Association International Conference (AAIC 2022) in the Novel Clinical Trial Designs and Outcome Measures session. Dr. Tam’s oral presentation will take place on August 2nd at 9:55am PT at the San Diego Convention Center. More info at:

Perceiv AI to present Foresight AD, a novel prognostic tool to optimize Alzheimer's clinical trials, at the 14th Clinical Trials on Alzheimer's Disease conference (CTAD 2021)

Nov 4, 2021 | Montréal, Canada | Press release | One-pager

Perceiv AI to present Foresight AD™, a novel prognostic tool to optimize Alzheimer's clinical trials, at the 14th Clinical Trials on Alzheimer's Disease (CTAD 2021) conference.

New prognostic results on presymptomatic populations presented at AAIC 2021

July 26, 2021| Denver, USA | Poster

We're happy to be virtually attending AAIC 2021 (Alzheimer’s Association International Conference). Dr. Angela Tam is presenting our poster #54702: A machine learning enrichment strategy for presymptomatic cohorts in Alzheimer's disease clinical trials.


Perceiv AI joins NVIDIA Inception program

May 21, 2021 | Montréal, Canada | Inception program

Perceiv AI, announced it has joined the NVIDIA Inception program, which is designed to nurture startups revolutionizing industries with advancements in AI and data sciences.

More info about the NVIDIA Inception program here!


New international consortium €20M supported by the ITEA 3 program named Secur-e-Health initiative

April 21, 2021 | Montréal, Canada | Project page

Perceiv AI announced a new international consortium project named Secure-e-Health initiative of €20M supported by the ITEA 3 program and will provide their expertise and AI-driven prognostic and predictive tools to this 8-country project’s 34 academic and private-sector partners. Drawing from several new technologies of partners, this ITEA3 project will create a fully integrated technology stack capable of supporting secure and privacy-preserving data analysis over fully separated datasets. The hope here is to remove some of the data silos that have prevented health innovation while preserving the privacy and security of that sensitive data between partners.

Betsabeh Madani Hermann becomes business and strategy advisor of Perceiv AI

April 14, 2021 | Montréal, Canada | Announcement

Ms. Madani Hermann is a strategy and innovation executive seasoned in general operations, commercialization, growth planning and execution across health and tech companies.

CQDM - Consortium de recherche biopharmaceutique

CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials

November 5, 2020 | Montréal, Canada | Announcement

The CQDM is pleased to announce the launch of a $600,000 collaborative project in biopharma and artificial intelligence (AI) to develop an AI-driven precision medicine tool.

Perceiv AI receives funding for development of Alzheimer's solution

August 24, 2020 | Montréal, Canada

Perceiv AI announces support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) in the form of advisory services and research and development funding totaling $180,000 CAD to advance our Alzheimer's disease solution.

CTA - Canadian Technology Accelerators

Canadian Technology Accelerator for Health - San Francisco has selected Perceiv AI for their 2020 program

August 4, 2020 | San Francisco, USA | CTA Health SF

Perceiv AI is proud to announce today that it has been selected to join the 2020 San Francisco Canadian Technology Accelerator for Health cohort. “We are delighted to join the CTA San Francisco accelerator’s 2020 cohort. We greatly look forward to working with leading life science industry mentors to help further develop our innovative, lifesaving technologies targeting neurodegenerative and cardiovascular diseases,” said CEO and co-founder Christian Dansereau.

Perceiv AI to present validation study at AAIC 2020 virtual event

July 27, 2020 | Montréal, Canada | Tweet

Perceiv AI presents a validation study of its prognostic enrichment tool for cognitive decline at the AAIC 2020 virtual conference - "Validation and Replication of a Prognostic Machine Learning Model for Enrichment of Cognitive Decliners in Clinical Trials".